- Home
- XNET vs INMB Comparison
XNET vs INMB Comparison
Compare XNET & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNET
- INMB
- Stock Information
- Founded
- XNET 2003
- INMB 2015
- Country
- XNET China
- INMB United States
- Employees
- XNET N/A
- INMB N/A
- Industry
- XNET Computer Software: Prepackaged Software
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- XNET Technology
- INMB Health Care
- Exchange
- XNET Nasdaq
- INMB Nasdaq
- Market Cap
- XNET 373.0M
- INMB 176.5M
- IPO Year
- XNET 2014
- INMB 2019
- Fundamental
- Price
- XNET $4.73
- INMB $2.26
- Analyst Decision
- XNET
- INMB Buy
- Analyst Count
- XNET 0
- INMB 4
- Target Price
- XNET N/A
- INMB $9.53
- AVG Volume (30 Days)
- XNET 1.0M
- INMB 6.7M
- Earning Date
- XNET 08-12-2025
- INMB 07-31-2025
- Dividend Yield
- XNET N/A
- INMB N/A
- EPS Growth
- XNET N/A
- INMB N/A
- EPS
- XNET N/A
- INMB N/A
- Revenue
- XNET $331,614,000.00
- INMB $50,000.00
- Revenue This Year
- XNET N/A
- INMB $82.14
- Revenue Next Year
- XNET N/A
- INMB $28,750.98
- P/E Ratio
- XNET N/A
- INMB N/A
- Revenue Growth
- XNET N/A
- INMB N/A
- 52 Week Low
- XNET $1.46
- INMB $1.89
- 52 Week High
- XNET $7.19
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- XNET 50.93
- INMB 25.52
- Support Level
- XNET $4.41
- INMB $2.22
- Resistance Level
- XNET $4.60
- INMB $2.77
- Average True Range (ATR)
- XNET 0.26
- INMB 1.04
- MACD
- XNET 0.01
- INMB -0.39
- Stochastic Oscillator
- XNET 72.48
- INMB 3.79
About XNET Xunlei Limited
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.